HealthPrize Technologies appoints board of advisers

Norwalk-based HealthPrize Technologies LLC recently formed a board of advisers to help guide the medication-adherence company’s growth.

A company spokeswoman said the advisers ”“ Katherine Milkman, Walid Gellad, Gabe Zichermann, James Kalustian and Michael Lewis ”“ will provide a range of expertise to HealthPrize, which provides an online/mobile platform aimed at getting patients to take their medication.

Milkman, an assistant professor at the University of Pennsylvania’s Wharton School, focuses her research on big data to document the ways people deviate from making optimal choices. She examines what factors cause one to lose self-control.

Gellad is an assistant professor of medicine at the University of Pittsburgh School of Medicine and assistant professor of health policy and management in the university”™s Graduate School of Public Health, as well as an adjunct scientist at the Rand Corp. He is an authority on the topic of medication adherence, HealthPrize reported.

Zichermann is chairman of GSummit, a gathering for experts across industries to share insights about “gamification,” using game-like approaches to engage customers. He has authored books on how leaders can leverage gamification strategy in the face of competition. He co-founded the strategic consultancy and product lab Dopamine, where he works with brands and startups.

Kalustian is the former chairman of Ambassadors Group, an educational travel company, and former chief operating officer of RxAnte, a venture-backed information technology company that focuses on improving health through focusing on medication adherence for chronic disease.

Lewis, a management consultant providing strategic and financial advice to health care companies and health care investment firms, formerly served as head of strategy and business development at Prodigy Health, a $600 million Aetna subsidiary. He was a member of Aetna’s corporate development and strategy group, securing a number of acquisitions, strategic alliances and joint ventures, HealthPrize reported.